A simple finger prick could revolutionize how doctors diagnose Alzheimer’s disease, according to researchers at the University of Gothenburg in Sweden.
The researchers have developed a breakthrough method of testing for the disease that requires only a few drops of blood from a fingertip that is then dried on a card. The new test could replace the expensive brain scans and invasive spinal taps that currently stand between millions of patients and a timely diagnosis.
In a study involving 337 participants, neuroscientist Nicholas Ashton and his team measured proteins associated with Alzheimer’s disease and achieved promising results.
The test focuses on:
- P-tau217, a key marker of the disease
- GFAP, a protein released when brain support cells experience stress
- NfL, fragments from damaged nerve cells
All of these proteins serve as warning signals of brain changes occurring in Alzheimer’s patients.
How well does the test work?
The scientists developed a simple finger-prick blood test for Alzheimer’s disease that uses dried blood spots on a card. The test measured p-tau217 levels that matched standard blood tests and detected Alzheimer’s-related changes in spinal fluid with 86% accuracy.
The two additional brain health markers, GFAP and NfL, also proved reliable when measured this way.
The timing of such a testing advancement is crucial. Alzheimer’s disease affects an estimated 7.2 million Americans age 65 and older, with nearly three-quarters of those being 75 or older. The disease begins its destructive process 20 years or more before memory loss and other symptoms become apparent, yet diagnosis remains frustratingly slow.
The Fisher Center for Alzheimer’s Research Foundation reports that patients wait an average of three-and-a-half years after symptoms appear before receiving confirmation.
With the new test, participants could collect their own samples without medical supervision, opening possibilities for testing in remote areas and among high-risk populations, including people with Down syndrome.
Potential drawbacks to the new method
While standard blood draws are less invasive than spinal fluid collection or neuroimaging, significant barriers exist beyond clinical settings. These include requirements for proper sample processing and temperature-controlled storage, plus the need for qualified personnel to perform the collection.
The research team emphasizes that the new testing technique requires additional study before clinical implementation.
In a summary of the findings, Ashton said:
“While we’re still years away from clinical use, we’re opening doors to research that was previously impossible – studying diverse populations, conducting large-scale screening studies, and including communities that have been historically underrepresented in Alzheimer’s studies.”
If validated through further research, this accessible testing method could enable large-scale studies and worldwide screening programs, dramatically accelerating the path to diagnosis.
Earlier detection would provide numerous benefits, including reducing patient anxiety, enabling informed decision-making and facilitating financial and care planning with families. It could also help encourage healthy lifestyle choices, and allow for timely safety adjustments.
Most importantly, earlier intervention could significantly improve outcomes and quality of life for millions facing this devastating disease.
Add a Comment